Compare Inovio Pharmaceuticals Inc (INO) vs Vanguard Mega Cap Growth ETF (MGK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Vanguard Mega Cap Growth ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Vanguard Mega Cap Growth ETF trades at $87.34. The key difference: Vanguard Mega Cap Growth ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | MGK | |
|---|---|---|
Market Cap | $89.27M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $2.87 | $92.06 |
52-Week Low | $1.05 | $70.70 |
Enterprise Value | $60.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
MGK, the Vanguard Mega Cap Growth ETF, trades at $86.83 with no recent price change. The technical outlook is bearish based on moving averages, while oscillators are neutral. Recent news highlights its low expense ratio of 0.05% and concentrated portfolio of 69 large-cap growth stocks, including heavy exposure to technology leaders. A 1:5 stock split occurred on April 21, 2026, and a small dividend is scheduled for June 2026.
MGK offers exposure to top U.S. growth companies but faces risks from high concentration in tech stocks and market volatility. Its long-term performance history and cost efficiency present opportunities for growth-focused investors, though sector-specific downturns could impact returns significantly.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Vanguard Mega Cap Growth ETF
MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.
Read more on MGK →
